Clinical Report Interpretation - Mr. Pawan Saxena, 46M

1. UPPER GI ENDOSCOPY

Interpretation

• Grade A = one or more mucosal breaks each ≤5mm, not extending between the tops of two mucosal folds
• This is the mildest grade of erosive reflux esophagitis
• GE junction at 40cm is within normal limits (normal is 38-42cm in most adults)

• Represents superficial gastric inflammation/gastritis
• Can be due to H. pylori, NSAIDs, bile reflux, or stress
• Note: H. pylori rapid urease test or biopsy was apparently not done at this endoscopy

2. COMPLETE BLOOD COUNT

Interpretation

• Iron deficiency anemia (IDA): Typically shows elevated RDW (>14.5%) and low RBC count. This patient has normal RDW and elevated RBC - more consistent with thalassemia trait
• Beta-Thalassemia Trait: Characteristically shows elevated RBC count, low MCV/MCH, normal or slightly low Hb, and normal or low RDW - this patient fits this pattern very well
• Mentzer Index = MCV ÷ RBC = 80.7 ÷ 5.56 = 14.5 - A value <13 favors thalassemia trait; >13 favors IDA. This borderline value warrants further testing

3. SEROLOGY (HBsAg, HCV Ab, HIV Ab)

Interpretation

4. ULTRASOUND WHOLE ABDOMEN

Interpretation

• <7 kPa = No significant fibrosis (F0-F1)
• 7-10 kPa = Borderline/Significant fibrosis (F1-F2)
• 10-13 kPa = Advanced fibrosis (F3)

• 13 kPa = Cirrhosis (F4)

INTEGRATED CLINICAL PICTURE

• Moderate hepatomegaly
• Fatty echogenic liver
• Coarse parenchymal texture
• LSM 9-10 kPa (F2 fibrosis)
• Negative viral markers (HBV, HCV, HIV negative)

• Erosive GERD (Grade A esophagitis) - mildest grade, but symptomatic (dyspepsia)
• Fundal gastritis - needs H. pylori testing
• Duodenum not assessed - relook scopy needed

• Microcytic hypochromic pattern with elevated RBC - likely beta-thalassemia trait (requires HPLC confirmation) vs. IDA

RECOMMENDED NEXT STEPS

1. Relook endoscopy (as planned) - to assess duodenum, and ideally biopsy for H. pylori
2. H. pylori testing (breath test or stool antigen) - given gastritis
3. Liver workup: LFTs (ALT, AST, ALP, GGT, bilirubin, albumin), serum ferritin, fasting glucose, HbA1c, lipid profile, insulin resistance markers
4. Hemoglobin electrophoresis/HPLC - to clarify the microcytic hypochromic CBC pattern
5. Lifestyle counseling - weight loss, alcohol cessation (if applicable), exercise, and diet modification are the cornerstones of MASLD management
6. Consider hepatology referral given F2 fibrosis on elastography

Disclaimer: This is a clinical interpretation for informational purposes. All management decisions should be made by the treating gastroenterologist based on the full clinical history, examination, and their professional judgment.

Recent Guidelines: Managing MASLD with Early Fibrosis (F2)

Guideline Sources

1. EASL-EASD-EASO Clinical Practice Guidelines (2024) - J Hepatol 2024;81:492-542 [PMID: 38851997] - the most comprehensive joint guideline
2. AASLD Practice Guidance Update (November 2025) - Hepatology 2026 [PMID: 41201884] - specifically updated for semaglutide in MASH with F2-F3 fibrosis

Framework: Stepwise Management for MASLD with F2 Fibrosis

Step 1 - Risk Stratification (Already Done for This Patient)

Step 2 - Lifestyle Modification (Cornerstone - All Guidelines)

• ≥5% body weight loss - improves steatosis
• ≥7-10% body weight loss - reduces liver inflammation (MASH resolution)
• ≥10% body weight loss - improves fibrosis

• Mediterranean diet is the most evidence-supported pattern
• Reduce saturated fats, refined carbohydrates, fructose, and ultra-processed foods
• Avoid alcohol entirely (even moderate alcohol accelerates fibrosis in MASLD)
• Limit soft drinks and added sugars

• 150-300 min/week of moderate aerobic exercise
• Resistance training 2-3x/week adds benefit
• Even without weight loss, exercise independently reduces liver fat

Step 3 - Pharmacotherapy for MASLD with F2 Fibrosis

A. Resmetirom (Rezdiffra) - THR-β agonist

• FDA approved March 2024 for non-cirrhotic MASH with significant fibrosis (F2-F3)
• EASL-EASD-EASO 2024: adults with non-cirrhotic MASH + stage ≥F2 should be considered for resmetirom
• MAESTRO-NASH Phase 3 trial: achieved MASH resolution and ≥1-stage fibrosis reduction
• Not yet widely approved outside the USA - check local availability

B. Semaglutide 2.4 mg/week (Wegovy) - GLP-1 receptor agonist

• FDA accelerated approval August 2025 specifically for MASH with F2-F3 fibrosis
• AASLD November 2025 update provides the most current implementation guidance
• ESSENCE Phase 3 trial interim results at 72 weeks:
  • MASH resolution without fibrosis worsening: 62.9% vs 34.3% placebo (p<0.001)
  • ≥1-stage fibrosis reduction without MASH worsening: 36.8% vs 22.4% placebo (p<0.001)
• Patient selection for semaglutide: VCTE LSM 8-15 kPa (this patient fits perfectly at 9-10 kPa)

C. Incretin-based therapies broadly

• GLP-1 RAs (liraglutide, semaglutide) and GLP-1/GIP co-agonist tirzepatide are endorsed by EASL-EASD-EASO 2024 for patients with T2DM or obesity co-existing with MASLD
• Tirzepatide showed impressive reductions in liver steatosis in the SURMOUNT-NASH trial

Step 4 - Managing Metabolic Comorbidities

Step 5 - Monitoring Protocol

• LFTs (ALT, AST): Every 3-6 months initially; annually once stable
• FIB-4 / LSM (Fibroscan): Every 1-2 years to monitor fibrosis progression/regression
• HCC surveillance: Generally not required at F2 (no cirrhosis), but reassess if fibrosis progresses
• Cardiovascular risk assessment: Annual (MASLD carries high CV event risk independent of liver disease)
• Relook endoscopy: As already planned (for this patient's GERD Grade A + gastritis)

Step 6 - Bariatric Surgery

Summary: What This Means for Mr. Pawan Saxena